EMA Deals with Manufacturing Deficiencies for Cancer Medicine The European Medicines Agency has recommended that the anticancer medicine DepoCyte be recalled from EU countries following the discovery of manufacturing deficiencies at Pacira Pharmaceuticals’ San Diego site. More...
Pharma's First Facebook game Boehringer Ingelheim has announced the beta launch of its Facebook game, Syrum, which is the first game of its kind to be developed by a pharmaceutical company. More...
The Foundation for the National Institute of Health Seeks Public Comment A US public–private partnership managed by the non-profit Foundation for the National Institutes of Health and chaired by FDA is seeking public feedback on the priorities, infrastructure tasks and research tasks it has proposed for 2013–2016. More...
Join our community on LinkedIn Want to discuss any of this week's news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More...
Realize Effective Pharmaceuticals
Reliable solutions enable pharmaceutical scientists to innovate in disease research, accelerate drug discovery and have greater confidence throughout development and manufacturing. Agilent solutions in genomics research, automation, separation and detection technologies along with workflow driven software solutions helps deliver the answers to bring effective therapeutics to market.
Learn about pharmaceutical purification, purity, and impurity analyses at www.agilent.com/lifesciences/realizepharma
Agilent
Advances in Label-Free Technology (Video) – Click to Watch Watch this customer success story as told by GSK in this video. Learn how you too can unlock challenging targets, simplify assay design, and shorten time to results with the Agilent RapidFire System. In this video, GSK presents the findings from their studies using the RapidFire High-throughput Mass Spectrometry System in various stages of the lead discovery process. Re-Imagine Mass Spectrometry Throughput Watch the video
Do you think large drug settlements to settle criminal and civil liabilities are an appropriate deterrent to corporate malpractices such as unlawful promotion of drugs and failure to report safety data?
Yes
76%
No
24%
This week we would like to know...
Has your company started implementing procedures and practices required by Europe's new pharmacovigilance legislation?
